title: [Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
abstract: BACKGROUND
  The incidence of acute myeloid leukemia is 3 cases per 100,000 inhabitants/year and its five years event free survival is 15 to 20%. Since the incorporation of trans retinoic acid, event free survival of M3 acute myeloid leukemia is 80%.
  
  
  OBJECTIVE
  To report the results of acute myeloid leukemia treatment at the Hospital del Salvador, between 1990 and 1998.
  
  
  METHODS
  The medical records of 117 patients (66 female, mean age 48.2 years), treated between 1990 and 1998 using PANDA protocol, were retrospectively reviewed. Immunophenotyping was done in 69 patients and cytogenetic studies were done in 65.
  
  
  RESULTS
  Sixteen percent of patients had M3 acute myeloid leukemia. The most frequent phenotype was the association of DR, CD34 plus a panmyeloid marker. DR and CD34 were negative in seven of nine patients with M3 acute myeloid leukemia. Cariotype was abnormal in 78% of patients. Complete remission was achieved in 65% of cases with a 13% of failures. Early mortality was 21.3% and decreased to 6.1% in the last three years. Infections and coagulation disorders were the main causes of death. Mean survival was 10.5 months. Five years event free survival was 11%. In M3 acute myeloid leukemia, the figure is 50%.
  
  
  CONCLUSIONS
  Treatment results are less effective than protocols that consider more aggressive chemotherapeutic protocols or bone marrow transplantation. The reduction in early mortality is due to a better management of febrile neutropenia.
authors.affiliation: Hospital del Salvador, Servicio de Medicina, Sección de Hematología, Departamento de Medicina Oriente, Facultad de Medicina, Universidad de Chile. bpuga@surfree.cl
authors.forename: B L
authors.initials: BL
authors.lastname: Puga
authors.forename: M E
authors.initials: ME
authors.lastname: Cabrera
authors.forename: M S
authors.initials: MS
authors.lastname: Undurraga
authors.forename: R
authors.initials: R
authors.lastname: Etcheverry
authors.forename: R
authors.initials: R
authors.lastname: Vacarezza
authors.forename: G
authors.initials: G
authors.lastname: Ducach
authors.forename: H
authors.initials: H
authors.lastname: Toledo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D016130:Immunophenotyping; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin